Lifecore Biomedical, Inc. \De\ M&A Deal with Lifecore Inc.
Lifecore Biomedical announced that the Department of Justice and the Federal Trade Commission granted early termination of the HSR Act waiting period for its pending merger with Lifecore Inc. This satisfies a key regulatory closing condition for the transaction, which remains subject to stockholder approval and other customary conditions. Lifecore Biomedical will become a wholly owned subsidiary of Lifecore Inc. upon completion of the deal.
Lifecore Biomedical, Inc. \De\ M&A Deal with Lifecore Inc.
Lifecore Biomedical established November 4, 2026, as the record date for a special meeting of stockholders to vote on its previously announced merger agreement with Lifecore Inc. and Hazel Merger Sub, Inc. The company will file a proxy statement to solicit shareholder approval for the adoption of the merger agreement.
Lifecore Biomedical, Inc. \De\ Wins Contract from Alcon Research, LLC
Lifecore Biomedical extended its contract manufacturing agreement with Alcon Research, LLC, pushing the expiration date from 2031 to December 31, 2034. The amendment establishes Alcon's minimum purchase obligations through the new term and includes a non-compete provision regarding certain products starting in November 2026.
Lifecore Biomedical, Inc. \De\ Signs $664M M&A Deal with Webster Equity Partners
Lifecore Biomedical has entered into a definitive agreement to be acquired by Webster Equity Partners for up to $663.7 million. Common stockholders will receive $6.28 per share in cash at closing plus contingent value rights (CVRs) worth up to an additional $160 million in aggregate based on performance milestones. The transaction represents a 49.5% premium to the company's last closing price and will result in Lifecore becoming a privately held company.